Medpace(US:MEDP)2026-02-10 15:00Financial Data and Key Metrics Changes - Revenue in Q4 2025 was $708.5 million, representing a year-over-year increase of 32% [5][6] - Full year 2025 revenue was $2.53 billion, a 20% increase from 2024 [5][6] - EBITDA for Q4 2025 was $160.2 million, up 20% from $133.5 million in Q4 2024 [6][7] - Full year EBITDA was $557.7 million, a 16.1% increase from the prior year [7] - Net income for Q4 2025 was $135.1 million, a 15.5% increase compared to $117 million in the prior year [7][8] - Full year net income was $451.1 million, an 11.6% increase from $404.4 million in 2024 [8] Business Line Data and Key Metrics Changes - Net new business awards entering backlog in Q4 increased 39.1% year-over-year to $736.6 million [5] - Ending backlog as of December 31, 2025, was approximately $3 billion, a 4.3% increase from the prior year [5] - Backlog conversion rate in Q4 was 23.6% of beginning backlog [5] Market Data and Key Metrics Changes - Cancellations were elevated in Q4, resulting in the highest backlog cancellations in over a year [4] - The net book-to-bill ratio was 1.04, lower than anticipated due to increased cancellations [4] Company Strategy and Development Direction - The company rates the overall business environment as adequate and improving [4] - There is an expectation for accelerated hiring in 2026, with a focus on mid to high single-digit growth [15] - The company anticipates a shift in the therapeutic area concentration, with metabolic trials expected to normalize as a percentage of revenue [31] Management's Comments on Operating Environment and Future Outlook - Management noted that the business environment remains reasonably good, with RFPs up slightly [18] - There is no significant change in decision-making or project progression despite elevated cancellations [55] - The company does not foresee a long-term risk from the concentration in the metabolic area [31] Other Important Information - Full year 2026 total revenue is expected to be in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 [9] - The company plans to maintain a focus on improving efficiency through technology and AI applications [65] Q&A Session Summary Question: What is embedded in your guidance for revenue growth excluding pass-throughs? - The company does not provide guidance on direct service revenue but expects reimbursable costs to be consistent with previous expectations [12][13] Question: What do you expect headcount growth to be in 2026? - The company anticipates hiring in 2026 to be above 25 levels, in the mid to high single-digit growth area [14] Question: Can you unpack the business environment and RFP activity? - The business environment is reasonably good, with RFPs up slightly, but cancellations led to missing expectations [18] Question: Can you provide details on cancellations? - Cancellations were widespread and not concentrated in any single project or client [24][22] Question: How do you view the competitive landscape? - The competitive landscape remains stable, with no significant changes in dynamics observed [59] Question: What are your thoughts on AI and its impact? - The company believes it is too early to determine the long-term impact of AI, with expectations for gradual changes [51]